Icure Pharmaceutical Incorporation (KOSDAQ:175250)

KOSDAQ:175250 Revenue

Icure Pharmaceutical Incorporation had revenue of 32.19B KRW in the quarter ending March 31, 2026, with 45.46% growth. This brings the company's revenue in the last twelve months to 93.45B, up 64.23% year-over-year. In the year 2025, Icure Pharmaceutical Incorporation had annual revenue of 83.38B with 64.45% growth.

• Revenue (ttm): 93.45B
• Revenue Growth: +64.23%
• P/S Ratio: 0.87
• Revenue / Employee: 424.75M
• Employees: 220
• Market Cap: 81.09B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	83.38B	32.68B	64.45%
Dec 31, 2024	50.71B	-6.10B	-10.74%
Dec 31, 2023	56.81B	-2.56B	-4.31%
Dec 31, 2022	59.37B	-4.92B	-7.65%
Dec 31, 2021	64.28B	-25.86B	-28.69%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 3, 2026

Data Sources Report a data error